# Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

> **NCT02574728** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 46 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Celecoxib
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02574728
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574728, "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02574728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*